Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GBT

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

Global Blood Therapeutics logo

About Global Blood Therapeutics Stock (NASDAQ:GBT)

Advanced Chart

Key Stats

Today's Range
$68.49
$68.49
50-Day Range
$68.07
$68.49
52-Week Range
$21.65
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

Global Blood Therapeutics Inc (GBT)
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
GBT Technologies to acquire Nexus Workspaces from CGI
See More Headlines

GBT Stock Analysis - Frequently Asked Questions

Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its quarterly earnings data on Thursday, November, 4th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.03. Global Blood Therapeutics's revenue was up 41.1% compared to the same quarter last year.

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Meta Platforms (META), Intel (INTC), Bristol Myers Squibb (BMY) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/04/2021
Today
7/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GBT
CIK
1629137
Fax
N/A
Employees
457
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$303.09 million
Net Margins
-137.30%
Pretax Margin
-137.01%
Return on Equity
-170.37%
Return on Assets
-39.24%

Debt

Debt-to-Equity Ratio
4.92
Current Ratio
6.88
Quick Ratio
6.17

Sales & Book Value

Annual Sales
$194.75 million
Price / Sales
23.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.05 per share
Price / Book
22.46

Miscellaneous

Outstanding Shares
67,476,000
Free Float
64,170,000
Market Cap
$4.62 billion
Optionable
Optionable
Beta
0.45

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:GBT) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners